Semaglutide 1 mg Units: Clinical Dosage Guide

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

One milligram of semaglutide contains 3.4 units—a fundamental conversion that matters whether you're managing type 2 diabetes or exploring weight management options. This standardized ratio applies across most compounded formulations, but understanding the math behind your dose is only part of the equation.

Dosage precision goes beyond unit conversions. Biomarkers, body composition, metabolic function, and genetic factors in peptide-pathway genes influence how individuals respond to treatment escalation. PlexusDx integrates this context to help you and your provider make more informed decisions about dosing strategy.

The Unit-to-Milligram Conversion Explained

Semaglutide concentration in compounded formulations is typically 1 mg per 0.294 mL, yielding 3.4 units per milligram. This ratio remains consistent across licensed 503A compounding pharmacies, making it safe and predictable for dose tracking and pen or syringe calibration.

Understanding this conversion prevents medication errors and ensures you can reliably track what you're actually injecting each week. If your provider prescribes 0.5 mg weekly, that equals 1.7 units—a level many patients start with before titrating upward based on response and tolerability.

Semaglutide Dosage Tiers: Units, Milligrams, and Clinical Context

Semaglutide dosing follows a stepwise escalation protocol. Most treatment plans begin at low doses and titrate weekly or bi-weekly to minimize gastrointestinal side effects while maximizing clinical benefit. The table below maps common dose milestones to their unit equivalents and typical clinical use.

Weekly Dose (mg)	Unit Equivalent	Common Clinical Use	Typical Escalation Week
0.25	0.85	Initial tolerability assessment	Week 1–4
0.5	1.7	Standard maintenance start	Week 4–8
1.0	3.4	Efficacy escalation point	Week 8–12
2.4	8.16	Maximum FDA-studied dose (diabetes/weight management)	Week 16+

Biomarker and Metabolic Factors That Influence Dosing Response

Your response to a given semaglutide unit dose depends partly on baseline metabolic markers: fasting glucose, HbA1c, insulin resistance indices, and lipid profiles. These biomarkers provide context for whether standard titration schedules suit your physiology or whether slower escalation is warranted.

GLP-1 receptor signaling also involves genetic variation. The GLP1R rs6923761 polymorphism and other peptide-pathway variants may influence how efficiently your body's GLP-1 receptors bind and respond to the medication. A qualified provider can use this genetic context alongside clinical markers to personalize your dosing strategy.

Safety Considerations and Provider-Guided Dosing

Semaglutide dosing adjustments should always occur under qualified healthcare provider supervision. Rapid escalation can trigger nausea, vomiting, and dehydration—especially in individuals with slower gastric emptying or pre-existing GI conditions. Your provider may recommend slower titration or biomarker reassessment before advancing doses.

Certain individuals—including those with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe renal or hepatic impairment, or acute pancreatitis—should not use semaglutide. Even unit-by-unit dosing precision cannot override absolute contraindications, so comprehensive medical evaluation is essential before starting any GLP-1 therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines genetic variation in GLP1R, GIPR, FTO, and MC4R pathways—markers that may help provide context for how your body's receptor signaling machinery handles GLP-1 therapy at various unit doses. Understanding these predispositions can support a more informed conversation with your provider about dosing strategy.

The genetic test does not predict your exact medication response or guarantee specific outcomes. Instead, it reveals predispositions in peptide-pathway genes that, combined with your biomarkers and clinical presentation, should be interpreted with a qualified healthcare provider to inform more personalized dosing decisions.

Many patients benefit from baseline genetic and biomarker assessment before starting semaglutide—whether at 0.25 mg (0.85 units) or a higher starting dose. This information helps your provider anticipate tolerability, adjust titration pace, and optimize the dose at which you achieve your clinical goals safely.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.